We have previously reported that serotonin (5-hydroxytryptamine [SHT]) alters cultured bovine pulmonary artery smooth muscle cell (SMC) configuration through two different regulatory mechanisms. We now report that 5HT also regulates SMC growth through these same two mechanisms-a stimulatory event initiated intracellularly and inhibition of growth resulting from a cell surface action. 5HT (1 ,M) plus 0.1 mM iproniazid (a 5HT metabolic inhibitor) produced a severalfold stimulation of DNA synthesis (as measured by ['H]thymidine incorporation) of SMCs after a 17-24-hour incubation with only a slight elevation of cellular cAMP. This stimulatory effect responded synergistically with other growth factors including plateletderived growth factor, fibroblast growth factor, and epidermal growth factor and was effectively reversed by 5HT uptake inhibition. It was not produced by 5-hydroxyindoleacetic acid, a metabolite of 5HT. In the presence of 1 pM 5HT plus 0.1 mM isobutylmethylxanthine (IBMX), cAMP was elevated eightfold, dendritic formation occurred, and ['H]thymidine labeling of SMCs was inhibited. Inhibition of labeling by ['H]thymidine was mimicked by other agents that elevated cellular cAMP (10 ,uM histamine, 1 ,M isoproterenol plus 0.1 mM IBMX, and 10 ,uM forskolin) and by 1 mM dibutyryl cAMP. This inhibitory effect was not blocked by either inhibition of 5HT uptake or 5HT-receptor antagonists ketanserin (5HT2); methiothepin, spiperone, and mianserin (5HT1/5HT2); and 3-tropanyl-indole-3-carboxylate and 3-tropanyl-3,5-dichlorobenzoate (5HT3). However, similar to 5HT, the 5HT,A agonist, (+)-8-hydroxy-(+)-2-dipropylamino-8-hydroxy-1,2,3,4-tetrahydronaphthalenehydrobromide, in association with IBMX, produced an elevation in cAMP and inhibition of labeling by [3H]thymidine. 5HT, in the presence of either iproniazid or IBMX, did not alter [Ca21]i, indicating that [Ca 2]i was not a signal for either of these actions. The studies show that 5HT affects SMC growth at two foci of action, one intracellularly by a currently unknown mechanism and another at the cell surface, perhaps via a novel receptor and dependent on transduction of the signal through elevation of cAMP. (Circulation Research 1991;68:1362-1368 R ecent studies showing effects of vasoactive agents such as angiotensin II, arginine vasopressin, substance P, and vasoactive intestinal polypeptide on cell growth1-3 and effects of growth factors, such as platelet-derived growth factor (PDGF) and epidermal growth factor (EGF), on smooth muscle contractility4 suggest a relation between growth and contractility of smooth muscle cells (SMCs). Serotonin (5-hydroxytryptamine [5HT]) is known to influence SMC contractility5-7 and has also been found to produce a mitogenic effect on cultured aortic SMCs,8-10 fibroblasts,1" glomerular mesangial cells,12 and neurons or neuroblasts.13 Stimulation of mitogenicity via specific receptor mechanisms has been postulated, but the mechanism for this appears to differ among cell types and species. Both positive and negative effects of elevated cellular cAMP on cellular proliferation have been noted in the literature, but until our recent testing of 5HT on SMC cAMP in the presence of isobutylmethylxanthine (IBMX),14 an inhibitor of phosphodiesterase, large elevations of cellular cAMP had not been reported to occur in vascular SMCs exposed to 5HT.
We have previously reported that serotonin (5-hydroxytryptamine [SHT]) alters cultured bovine pulmonary artery smooth muscle cell (SMC) configuration through two different regulatory mechanisms. We now report that 5HT also regulates SMC growth through these same two mechanisms-a stimulatory event initiated intracellularly and inhibition of growth resulting from a cell surface action. 5HT (1 ,M) plus 0.1 mM iproniazid (a 5HT metabolic inhibitor) produced a severalfold stimulation of DNA synthesis (as measured by ['H]thymidine incorporation) of SMCs after a 17-24-hour incubation with only a slight elevation of cellular cAMP. This stimulatory effect responded synergistically with other growth factors including plateletderived growth factor, fibroblast growth factor, and epidermal growth factor and was effectively reversed by 5HT uptake inhibition. It was not produced by 5-hydroxyindoleacetic acid, a metabolite of 5HT. In the presence of 1 pM 5HT plus 0.1 mM isobutylmethylxanthine (IBMX), cAMP was elevated eightfold, dendritic formation occurred, and ['H]thymidine labeling of SMCs was inhibited. Inhibition of labeling by ['H]thymidine was mimicked by other agents that elevated cellular cAMP (10 ,uM histamine, 1 ,M isoproterenol plus 0.1 mM IBMX, and 10 ,uM forskolin) and by 1 mM dibutyryl cAMP. This inhibitory effect was not blocked by either inhibition of 5HT uptake or 5HT-receptor antagonists ketanserin (5HT2); methiothepin, spiperone, and mianserin (5HT1/5HT2); and 3-tropanyl-indole-3-carboxylate and 3-tropanyl-3,5-dichlorobenzoate (5HT3). However, similar to 5HT, the 5HT,A agonist, (+)-8-hydroxy-(+)-2-dipropylamino-8-hydroxy-1,2,3,4-tetrahydronaphthalenehydrobromide, in association with IBMX, produced an elevation in cAMP and inhibition of labeling by [3H]thymidine. 5HT, in the presence of either iproniazid or IBMX, did not alter [Ca21]i, indicating that [Ca 2]i was not a signal for either of these actions. The studies show that 5HT affects SMC growth at two foci of action, one intracellularly by a currently unknown mechanism and another at the cell surface, perhaps via a novel receptor and dependent on transduction of the signal through elevation of cAMP. (Circulation Research 1991;68:1362-1368) R ecent studies showing effects of vasoactive agents such as angiotensin II, arginine vasopressin, substance P, and vasoactive intestinal polypeptide on cell growth1-3 and effects of growth factors, such as platelet-derived growth factor (PDGF) and epidermal growth factor (EGF), on smooth muscle contractility4 suggest a relation between growth and contractility of smooth muscle cells (SMCs). Serotonin ) is known to influence SMC contractility5-7 and has also been found to produce a mitogenic effect on cultured aortic SMCs,8-10 fibroblasts,1" glomerular mesangial cells,12 and neurons or neuroblasts.13 Stimulation of mitogenicity via specific receptor mechanisms has been postulated, but the mechanism for this appears to differ among cell types and species. Both positive and negative effects of elevated cellular cAMP on cellular proliferation have been noted in the literature, but until our recent testing of 5HT on SMC cAMP in the presence of isobutylmethylxanthine (IBMX),14 an inhibitor of phosphodiesterase, large elevations of cellular cAMP had not been reported to occur in vascular SMCs exposed to 5HT.
We have previously found that 5HT causes a configurational change (dendritic formation) of bovine pulmonary artery SMCs in culture through actions at two different locations of the cell, one that requires 5HT uptake into the cell'5 and another that occurs through action of a receptor at the cell surface.14 We have used these observations to further assess influences of 5HT on SMC growth as measured by labeling with radioactive thymidine. Here, too, there are dual effects of 5HT. Cellular internalization of 5HT produces a stimulatory effect on labeling with [3H]thymidine, whereas elevation of cAMP through 5HT receptor action in the presence of IBMX elevates cellular cAMP and reduces ['H]thymidine incorporation into the cells. We propose from these experiments that 5HT is capable of modulating vascular SMC growth through both positive and negative effects that may be regulated by its extent of elevation of cellular cAMP.
Materials and Methods
Reagents RPMI 1640 medium, Dulbecco's phosphate-buffered saline (PBS), and fungizone (amphotericin B) were purchased from GIBCO Laboratories, Grand Island, N.Y. Penicillin G potassium was from E.R. Squibb & Sons, Inc., Princeton, N.J. Ketanserin and methiothepin were from Janssen Pharmaceutical Inc., Piscataway, N.J. Spiperone, mianserin HCl, 3-tropanyl-indole-3-carboxylate (ICS-205930), 3-tropanyl-3,5 -dichlorobenzoate (MDL-72222), 2(2,6-dimethoxyphenoxyethyl) aminomethyl-1,4 -benzodioxane hydrochloride (WB4101), and (+)-8-hydroxy-(+)-2dipropylamino-8-hydroxy-1,2,3,4-tetrahydronaphthalenehydrobromide (8-OH-DPAT) were from Research Biochemicals Inc., Natick, Mass. Fluoxetine was purchased from Eli Lilly and Company, Indianapolis, Ind. Bombesin was from Calbiochem Corp., La Jolla, Calif. Human recombinant EGF and fibroblast growth factor (FGF) were from PeproTech, Inc., Rocky Hill, N.J. Fetal bovine serum (FBS), human PDGF, and other agents were purchased from Sigma Chemical Co., St. Louis. Culture and Characterization of SMCs A modification of the method of Ross16 was used for the isolation and culture of SMCs. Bovine pulmonary arteries were rinsed twice with PBS (37°C) containing antibiotics (300 units/ml penicillin G potassium, 300 gg/ml streptomycin sulfate, and 1.25 gg/ml amphotericin B) and slit longitudinally on a sterile Petri dish. The luminal side of the vessel was scraped with a scalpel to remove endothelial cells, and the abluminal side was peeled to remove connective tissue. The medial layer was peeled away and cut into 1-cm2 strips. These explants were then placed intimal side down in a Falcon six-well plate for 10 minutes. Three milliliters of RPMI 1640 containing 10% FBS was added to each well, and the explants were incubated in a CO2 incubator for 7 days without disturbance. SMCs migrated out from the explant after 1 week in culture. The vessel explants were removed from the wells, and cells were fed every 2-3 days until they reached confluence. Cells were stored in liquid N2 for subculture. First-to fourth-passaged cells after the explants were used in these experiments. SMCs were characterized by morphology and fluorescent anti-muscle actin staining of first-passaged cells with antibody that was a gift from Dr. Ira Herman of Tufts University, Boston.
Assay of cAMP Content of Cells
Cells at confluence (106 cells/dish) were washed with prewarmed PBS and preincubated with IBMX or inhibitors for 20 minutes at 37°C. 5HT or other agents were then added to the dishes. Cells were collected after a 10-minute incubation with the agents tested. After extraction of cells with acetyl ether, the samples were lyophylized and resuspended in 50 mM sodium acetate buffer, pH 6.3. cAMP was assayed by a nonacetylation process using cAMP (1251) radioimmunoassay kits (Amersham Corp., Arlington Heights, Ill.) as previously described.17
Thymidine Incorporation
SMCs were seeded into 35-mm Petri dishes (Corning Glass Inc., Corning, N.Y.) at a density of 4x 104 cells/dish and allowed to proliferate for 72 hours. Cells were then growth-arrested for 48-72 hours in medium consisting of RPMI 1640 supplemented with 0.1% FBS and antibiotics. Cells were exposed to 5HT in this medium containing 0.6 mM ascorbic acid for 20 hours before labeling with [methyl-'H]thymidine (0.1 Ci/ml, specific activity 20 Ci/mmol, New England Nuclear Corp., Boston) in this medium for 4 hours. Iproniazid, IBMX, or other inhibitors were added 20 minutes before 5HT. These agents alone did not alter the thymidine incorporation by SMCs. Ascorbic acid added with 5HT to cells as an antioxidant produced a small stimulation of thymidine incorporation as previously reported,18 but this did not alter the results significantly. Some experiments were done with [3H]thymidine introduced concurrently with 5HT, and labeling was carried out for the entire incubation period. This is noted in "Results" where relevant. After labeling, experiments were terminated by aspirating the medium, and cells were washed with cold PBS, followed by cold 6% trichloroacetic acid. Cells were then dissolved in 0.2N NaOH, and radioactivity was counted in a liquid scintillation counter (model 1219, Pharmacia LKB Biotechnology Inc., Gaithersburg, Md.). Cell counts were done in parallel at, before, and after growth arrest and at termination of the experiment to assure that cells were indeed growth-arrested. Cells were removed with 0.1% trypsin and counted with a Coulter counter (model ZM, Coulter Corp., Hialeah, Fla.).
Results

Stimulatory Effect of 5HT on [3H]Thymidine
Labeling of SMCs Quiescent SMCs in culture responded to 1 ,uM 5HT in the presence of iproniazid, a monoamine oxidase inhibitor, with a 12-fold increase in [3H]thymidine incorporation into DNA (Figure 1 ). This effect was significantly reduced in the absence of iproniazid, and 5 -hydroxyindoleacetic acid (5-HIAA), the stable metabolite of 5HT, did not produce any increase in labeling with ['H]thymidine. The mitogenic effect of 5HT on SMCs was observed at a concentration of 5HT as low as 1 nM and was concentration dependent up to 10 ,uM 5HT ( Figure  2 ). The stimulation in ['H]thymidine incorporation in response to 5HT plus iproniazid required prolonged incubation. SMCs incubated with 5HT for up to 12 hours did not show any stimulation, but a 90% increase in thymidine incorporation into SMCs was observed after 17 hours and a sixfold increase was observed after a 24-hour incubation (Figure 3 ). The interactions of 5HT with other growth factors such as PDGF, FGF, and EGF were tested. PDGF (2 ng/ ml), FGF (0.5-1 ng/ml), and EGF (2-4 ng/ml) stimulated SMC labeling twofold to fourfold, and a synergistic mitogenic response was observed when SMCs were incubated with 5HT in the presence of these growth factors (Table 1) activates phosphoinositide-specific phospholipase C differently from these growth factors,19 did not stimulate labeling of SMCs when applied alone or in combination with 5HT (Table 1) .
Inhibitory Effect of SHT on [3H]Thymidine Labeling of SMCs
When SMCs were incubated in the presence of 0.1% FBS with 5HT plus IBMX, radioactive labeling of cells with ['H]thymidine was reduced by 40-70% at 2 hours of incubation (Figure 4 ). This inhibition persisted during prolonged incubations up to 24 hours. Incubation of SMCs with 5HT plus IBMX in medium supplemented with 5% FBS produced a similar result ( Table 2 ). The same effect was found with 10% FBS (data not shown). We have previously reported that 5HT plus IBMX elevates cAMP of SMCs eightfold.14 To determine if cAMP was in- volved in the inhibition of [3H]thymidine labeling, several cAMP-stimulating agents such as isoproterenol, forskolin, histamine, cholera toxin, 8-bromo cAMP, and dibutyryl cAMP were also tested. The radioactive labeling of SMCs was highly inhibited by all of these agents as shown in Table 3 .
Mechanisms of Stimulatory and Inhibitory Effects of SHT on SMC Labeling With [3H]Thymidine
Serotonin receptor antagonists such as ketanserin (5HT2 antagonist); methiothepin, spiperone, and mianserin (5HT1/5HT2 antagonists); and ICS-205930 and MDL-72222 (5HT3 antagonists) either did not or only partially reversed the stimulatory effect of 5HT plus iproniazid or the inhibitory effect of 5HT plus IBMX on labeling of cells with [3H]thymidine (Table  4 ). On the other hand, the 5HT uptake inhibitors imipramine and fluoxetine blocked the stimulation of [3H]thymidine produced by 5HT plus iproniazid in a dose-dependent manner ( Figure 5 ), but imipramine (10 ,uM) had no effect on the inhibition of labeling Figure 6 ) and a similar inhibition of SMC labeling with [3H]thymidine similar to that of 5HT (Figure 4 ), suggesting that the inhibitory effect of 5HT on thymidine labeling may be mediated through a 5HT1A receptor. 8-OH-DPAT plus iproniazid, however, did not produce stimulation of thymidine labeling (data Figure 6) . Similarly, imipramine, an inhibitor of 5HT uptake, only minimally reduced cAMP elevation ( Figure 6 ) and did not reverse the inhibition of labeling with ['H]thymidine produced by 5HT plus IBMX.
Discussion
We have previously shown that early-passaged SMCs respond to 5HT by developing a configurational change (dendritic formation) and that this change is blocked by inhibition of 5HT uptake. SMCs at higher passages retain the ability to transport 5HT but fail to respond morphologically. 15 We have also found that 5HT in the presence of IBMX, a phosa) C, CD 0 0 ,) Q 0 E 0-a2-0 phodiesterase inhibitor, produces a similar SMC dendritic change, regardless of cellular passage number, and is not dependent on cellular uptake of 5HT. The second configurational change is accompanied by a high elevation of cAMP and seems to involve activation of a SHT1A receptor. Thus, 5HT may alter SMC configuration from actions at both intracellular and extracellular sites.
We have now also found that 5HT regulates SMC growth in different directions (stimulatory or inhibitory) by actions at intracellular and extracellular sites. The stimulatory effect requires prolonged incubation and responds synergistically with growth factors such as PDGF, EGF, and FGF, but not with bombesin, which mediates different signal transduction pathways.'9 These findings are in agreement with earlier observations in bovine aortic SMCs by Nemecek et a18 that 5HT acts synergistically with PDGF in producing stimulation of DNA synthesis. However, we failed to find that the stimulatory effect was mediated through a 5HT2 receptor. In our system, inhibitors of 5HT uptake reversed the stimulation in a dose-dependent manner, and we conclude from these observations that 5HT must be internalized by the cells to stimulate DNA synthesis. The stimulatory effect is not produced by a metabolic product of 5HT, since it occurred in the presence of iproniazid, which prevents degradation, and since 5-HIAA, a stable metabolite, did not substitute for 5HT in its action.
Thus, it appears that 5HT, at some point either during the transport process or once inside the cell, is able to stimulate cellular labeling by ['H]thymidine.
We do not currently know the mechanism of this response. 5HT has been shown to stimulate phosphorylation of a 20,000-Da protein in aortic SMCs20 and of an 80,000-Da protein in rat glomerular mesangial cells12 through a 5HT2 receptor. It also induces the turnover of phosphoinositide and stimulation of protein kinase C (PKC), but PKC has been reported to have both proliferative21 and antiprolif-erative22 actions on SMCs. Kariya et a123 later concluded that there are two types of PKC with different functions in cultured rabbit SMCs. Takagi et a124 reported that stimulation of DNA synthesis induced by PDGF was inhibited by low concentrations of the PKC inhibitor, 1-(5-isoquinolinylsulfonyl)-2-methylpiperazine (H-7), indicating that PKC may play an important role in SMC proliferation. We have not directly measured PKC or phosphoinositol turnover of SMCs of bovine pulmonary artery in response to 5HT, but PKC inhibitors such as dihydrosphingosine and H-7 failed to reverse the mitogenic effect in our cells (authors' unpublished data). Also, downregulation of PKC with a high concentration of phorbol 12,13-dibutyrate (1 ,M for 48 hours) did not significantly affect stimulation of thymidine incorporation by 5HT (data not shown). We have also measured [Ca2+]i of SMCs in response to 5HT plus IBMX or iproniazid and found that there was no alteration of [Ca21i, indicating that both stimulation and inhibition of [3H]thymidine labeling due to 5HT are independent of changes in [Ca2+]i. Also, 0.4 mM EGTA in the medium did not affect stimulation or inhibition of labeling, supporting an absence of changes in Ca21 flux in the processes. Elevation of DNA synthesis of bovine aortic SMCs by 5HT has been reported to be accompanied by alterations of inositol phosphate and [Ca2+i.10 In these studies, preincubation of SMCs with pertussis toxin abolished the mitogenesis without affecting the inositol phosphate turnover and [Ca2+]i elevation produced by 5HT. In our system, pertussis toxin (5-10 ng/ml) did not influence either stimulatory or inhibitory growth effects (authors' unpublished data).
Unlike the stimulatory effect of 5HT that required an active uptake process, the inhibitory effect of 5HT on cellular labeling with [3H]thymidine was not blocked by inhibition of 5HT uptake, indicating a cell surface action. Furthermore, the inhibitory action was always associated with an elevation of cAMP.
Studies directed toward identifying a specific 5HT
receptor on the cell surface with known antagonists were unsuccessful. WB4101, a nonspecific inhibitor of the 5HT1A receptor, only partially blocked the effect of 5HT. Yet, both elevation of cAMP and inhibition of [3H]thymidine labeling were mimicked by 8-OH-DPAT, a reputed 5HTlA agonist. Further studies will be required to identify whether the 5HT receptor on our cells is novel or of the 1A variety.
5HTIA agonists have been shown to both depress and elevate cellular cAMP, depending on the type of cell under study. 25 The role of cyclic nucleotides in cellular growth and differentiation has been extensively reviewed.26 cAMP elevating agents, cAMP analogues, and phosphodiesterase inhibition have been shown to block proliferation of cultured bovine aortic endothelial cells,27,28 Chinese hamster lung fibroblasts,29 and SMCs.27,30,31 Elevation of cAMP, however, acted as a mitogenic signal for Swiss 3T3 cells32 and human microvascular endothelial cells. 3334 We have previously found that 5HT produces a high elevation of cAMP in SMCs, similar to that produced by other cAMP-elevating agents such as forskolin, isoproterenol, and histamine. 35, 36 Elevations of cAMP in our SMCs were accompanied by both cellular dendritic formation and inhibition of [3H]thymidine incorporation. However, a possible reduction of cell membrane surface area associated with dendritic formation was not related to the inhibition of [3H]thymidine labeling since labeling was enhanced by 5HT plus iproniazid in early-passaged cells that also showed dendritic formation.1' Higher-passaged cells, retaining the capability to transport 5HT, responded to 5HT plus iproniazed with stimulation of [3H]thymidine incorporation, but without a morphological response.
Thus, it appears that SMCs possess the machinery for 5HT to both elevate and reduce proliferative processes of the cells. The net results likely depend on factors regulating the level of cAMP at the time of introduction of 5HT.
